Mesenchymal Stem Cell Agent for Kidney CD25+ T Cell Increase
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IgA nephropathy and other renal diseases like glomerulonephritis are largely symptomatic, lacking a fundamental therapeutic approach.
Innovation Solution
An agent comprising mesenchymal stem cells, specifically designed to increase CD25-positive regulatory T cells in the kidneys, utilizing a cryopreservation solution with DMSO at a concentration of less than 5% (v/v), is administered to treat renal diseases, including glomerulonephritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If symptomatic therapies such as renin-angiotensin system inhibitors, adrenocortical steroid drugs, immunosuppressive drugs, and tonsillectomy are performed for IgA nephropathy, then symptoms can be managed, but fundamental therapy has not been obtained and the development of a therapy therefor has been desired
Solution Approach 1:
The patent uses mesenchymal stem cells as an intermediary substance to treat IgA nephropathy. These cells are administered to patients and work by differentiating into kidney tissue and modulating the immune system, providing a fundamental therapy rather than just symptom management. The stem cells act as a mediator between the patient's damaged kidney tissue and the healing process.
2Reliability
If mesenchymal stem cells are used for treatment of renal diseases, then fundamental therapy can be achieved, but the complexity of cell preparation and administration increases
Solution Approach 1:
The patent employs preliminary action by pre-preparing and cryopreserving mesenchymal stem cells before they are needed for treatment. The cells are harvested, expanded in culture, and frozen in liquid nitrogen storage at -196°C, allowing them to be stored indefinitely and administered on demand without requiring complex preparation at the time of treatment. This eliminates the need for complex coordination between cell harvesting and treatment timing.
3Productivity
If allogeneic mesenchymal stem cells are used, then commercialization becomes easier and stable effects can be obtained, but allogenic rejection may occur
Solution Approach 1:
The patent employs allogeneic (donor-derived) mesenchymal stem cells rather than autologous (patient-derived) cells. This allows the use of standardized, pre-prepared cell products that can be manufactured and stored in advance, making the therapy more commercially viable and easier to administer. The cells are essentially treated as disposable therapeutic products that are thawed and administered as needed.
Data Source
AI summary
The present invention addresses the problem of providing a fundamental therapeutic method for renal diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).